- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Asia Pacific Antiviral Drug Market – Size, Outlook, Trends and Forecast (2024 – 2032)
Antiviral Drugs are medicines which are used for treating viral infections. Most anti-viral drugs are used for particular viral diseases, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen. Instead, they hinder the development of those viruses.
Asia-Pacific Antiviral Drugs Market Segments Size & Growth:
Asia-Pacific Antiviral drug market size is projected to reach approximately $8.2 billion by the end of 2024 with a CAGR of close to 7.3% from $5.9 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increased Nanotechnology in Developing Antiviral Agents, Technical breakthroughs in the development of Antivirals, Increasing Unmet Needs and Population Growth. However, High Risk of Failure and Government Firmness, Increasing Market for Generics, Lack of a broad antiviral to treat multiple viral infections are thereby hampering the market growth.
Asia-Pacific Antiviral Drugs Market Segments Share:
Asia-Pacific Antiviral Drugs Market is categorised into a therapeutic area which comprises of HIV/AIDS Therapeutics Market, Hepatitis Therapeutics Market, Herpes Therapeutics Market, Influenza Therapeutics Market. Among the Therapeutic area, HIV/AIDS Therapeutics Market segment dominated the market in 2018. By Type, the market is segregated into branded and genetics. Among the Type, Genetics segment is projected to continue its dominant during the period 2018-2024. By Geography, India and China are expected to dominate the Asia-Pacific Antiviral Drugs market, and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.
Asia-Pacific Antiviral Drugs Market Trends:
- The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective. This technique will not only have a positive impact on viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above USD 100 and could be used to control an epidemic efficiently, can now be produced at 1% of its original cost.
- The use of combination therapy has proven to be beneficial to treat certain viral infections due to their synergistic effect. This therapy helps to prevent drug resistance acquired by the viral organism as the treatment contains more than one drug. Most of the drugs employed in the treatment of HIV are given in combination with other drugs to combat the opportunistic infections in HIV patients.
- Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved ISENTRESS, the company’s integrase inhibitor, for use in combination with other antiretroviral agents, for the treatment of HIV-1 in neonates – newborn patients from birth to four weeks of age – weighing at least 2 kg.
North America Antiviral Drugs Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Merck & Co
- MedImmune
- Johnson & Johnson
- GlaxoSmithKline
- Abbott Laboratories
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Increased Nanotechnology in Developing Antiviral Agents
4.1.2 Technical breakthroughs in the development of antivirals
4.1.3 Increasing Unmet Needs and Population Growth
4.2 Restraints
4.2.1 High Risk of Failure and Government Firmness
4.2.2 Increasing Market for Generics
4.2.3 Lack of a widespread antiviral to treat multiple viral infections
4.3 Opportunities
4.3.1 Access to Antiviral Drugs in Pharmerging Markets
4.3.2 Increasing Need for Broad-Spectrum Drugs
4.4 Challenges
4.4.1 High cost of developing drugs
4.4.2 Increasing usage of natural products for the development of Antiviral drug
5. Asia-Pacific Antiviral Drugs Market – By Therapeutic Area
5.1 Influenza Therapeutics Market
5.2 Herpes Therapeutics Market
5.3 Hepatitis Therapeutics Market
5.4 HIV/AIDS Therapeutics Market
6. Asia-Pacific Antiviral Drugs Market – By Type
6.1 Genetics
6.2 Branded
7. Asia-Pacific Antiviral Drugs Market – By Country
7.1.Introduction
7.2. India
7.3. China
7.4 Japan
7.5 Rest of Asia
8. Company Profiles
8.1 Schering-Plough
8.2 Roche Holding AG
8.3 Merck & Co
8.4 MedImmune
8.5 AstraZeneca
8.6 Johnson & Johnson
8.7 GlaxoSmithKline
8.8 Gilead
8.9 Bristol-Myers-Squibb
8.10 Abbott
8.11 AbbVie
8.12 Aurobindo Pharma
8.13 Mylan N.V.
8.14 Cipla
8.15 Novartis International AG
9. North America Antiviral Drugs Market – Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,489.86 - €7,469.57
- INR: ₹225,053.86 - ₹675,161.59
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £2,133.43 - £6,400.30
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Antiviral Drugs are medicines which are used for treating viral infections. Most anti-viral drugs are used for particular viral diseases, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen. Instead, they hinder the development of those viruses.
Asia-Pacific Antiviral Drugs Market Segments Size & Growth:
Asia-Pacific Antiviral drug market size is projected to reach approximately $8.2 billion by the end of 2024 with a CAGR of close to 7.3% from $5.9 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increased Nanotechnology in Developing Antiviral Agents, Technical breakthroughs in the development of Antivirals, Increasing Unmet Needs and Population Growth. However, High Risk of Failure and Government Firmness, Increasing Market for Generics, Lack of a broad antiviral to treat multiple viral infections are thereby hampering the market growth.
Asia-Pacific Antiviral Drugs Market Segments Share:
Asia-Pacific Antiviral Drugs Market is categorised into a therapeutic area which comprises of HIV/AIDS Therapeutics Market, Hepatitis Therapeutics Market, Herpes Therapeutics Market, Influenza Therapeutics Market. Among the Therapeutic area, HIV/AIDS Therapeutics Market segment dominated the market in 2018. By Type, the market is segregated into branded and genetics. Among the Type, Genetics segment is projected to continue its dominant during the period 2018-2024. By Geography, India and China are expected to dominate the Asia-Pacific Antiviral Drugs market, and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.
Asia-Pacific Antiviral Drugs Market Trends:
- The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective. This technique will not only have a positive impact on viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above USD 100 and could be used to control an epidemic efficiently, can now be produced at 1% of its original cost.
- The use of combination therapy has proven to be beneficial to treat certain viral infections due to their synergistic effect. This therapy helps to prevent drug resistance acquired by the viral organism as the treatment contains more than one drug. Most of the drugs employed in the treatment of HIV are given in combination with other drugs to combat the opportunistic infections in HIV patients.
- Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved ISENTRESS, the company’s integrase inhibitor, for use in combination with other antiretroviral agents, for the treatment of HIV-1 in neonates – newborn patients from birth to four weeks of age – weighing at least 2 kg.
North America Antiviral Drugs Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Merck & Co
- MedImmune
- Johnson & Johnson
- GlaxoSmithKline
- Abbott Laboratories
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Increased Nanotechnology in Developing Antiviral Agents
4.1.2 Technical breakthroughs in the development of antivirals
4.1.3 Increasing Unmet Needs and Population Growth
4.2 Restraints
4.2.1 High Risk of Failure and Government Firmness
4.2.2 Increasing Market for Generics
4.2.3 Lack of a widespread antiviral to treat multiple viral infections
4.3 Opportunities
4.3.1 Access to Antiviral Drugs in Pharmerging Markets
4.3.2 Increasing Need for Broad-Spectrum Drugs
4.4 Challenges
4.4.1 High cost of developing drugs
4.4.2 Increasing usage of natural products for the development of Antiviral drug
5. Asia-Pacific Antiviral Drugs Market – By Therapeutic Area
5.1 Influenza Therapeutics Market
5.2 Herpes Therapeutics Market
5.3 Hepatitis Therapeutics Market
5.4 HIV/AIDS Therapeutics Market
6. Asia-Pacific Antiviral Drugs Market – By Type
6.1 Genetics
6.2 Branded
7. Asia-Pacific Antiviral Drugs Market – By Country
7.1.Introduction
7.2. India
7.3. China
7.4 Japan
7.5 Rest of Asia
8. Company Profiles
8.1 Schering-Plough
8.2 Roche Holding AG
8.3 Merck & Co
8.4 MedImmune
8.5 AstraZeneca
8.6 Johnson & Johnson
8.7 GlaxoSmithKline
8.8 Gilead
8.9 Bristol-Myers-Squibb
8.10 Abbott
8.11 AbbVie
8.12 Aurobindo Pharma
8.13 Mylan N.V.
8.14 Cipla
8.15 Novartis International AG
9. North America Antiviral Drugs Market – Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.